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Summary
Background: Intra-articular (IA) hyaluronan (HA) injections are approved for the treatment of knee osteoarthritis (OA) pain. One of the
currently available products is approved for repeat treatment courses. While HA is classed as a symptom-modifying agent, there is
substantial evidence that this therapeutic modality also possesses disease-modifying activity.
Objective: A rabbit model of OA, anterior cruciate ligament transection (ACLT), was used to investigate the long-term effects of single and
sequential courses of HA therapy on OA progression.
Design: One or two courses of five weekly IA injections of sodium hyaluronate (Hyalgan®) average molecular weight, MW, of 500–730 kDa,
or vehicle were administered to rabbits (N10 per group), initiated 4 and 13 weeks (for groups that received a second course) after ACLT.
Gross morphological and histomorphometric evaluations were performed on harvested knee joints following sacrifice at 26 weeks after
surgery.
Results: All the rabbits exhibited the characteristic pathologic changes of OA. Rabbits that received one or two courses of HA injections
showed less disease progression than rabbits treated with ACLT alone or with 10 vehicle injections. However, rabbits that received five
vehicle injections also showed improved morphology compared with those given no injections. Rabbits that received 10 HA injections
showed significantly less surface roughness of the femoral cartilage compared with rabbits treated with ACLT, 5 HA injections, or 10 vehicle
injections, and showed significantly less surface roughness of the tibial plateau compared with all other treatment groups (P<0.05).
Conclusions: Repeat courses of HA injections reduced the degree of articular degeneration in a rabbit ACLT model of OA. Sequential
courses of HA therapy may be advantageous in the long-term management of OA.
© 2003 Published by Elsevier Ltd on behalf of OsteoArthritis Research Society International.
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Introduction
Intra-articular (IA) hyaluronan (HA) therapy is used for the
treatment of pain associated with osteoarthritis (OA) of
the knee. Clinical trials and clinical practice reports
have demonstrated that IA HA injections are effective and
associated with an excellent safety and tolerability
profile1–11. As with all other available non-surgical treat-
ments for OA, HA is currently viewed as treatment for only
the symptoms of OA12. However, development of pharma-
cologic treatments with the potential for structure-modifying
activity in the treatment of OA, also called chondro-
protective disease-modifying drugs for OA (DMOADs), has
become a major focus in the field of OA research. As
defined by the Osteoarthritis Research Society (OARS)
and the European Group for the Respect of Ethics and
Excellence in Science (GREES), such compounds retard
or stabilize the progression of established OA by altering
the underlying pathologic processes12. Although the estab-
lishment of structure-modifying activity does not require
demonstration of symptom-modifying activity, it is possible
that a single agent could possess both activities12.
There are growing preclinical and clinical data suggest-
ing that IA HA has disease-modifying activity, in addition to
its proven efficacy and safety in treating the pain of OA.
With the use of in vitro, animal and human models, HA has
been shown to exert a number of complex regulatory
effects on the environment of the synovium, the articular
cartilage, and the extracellular matrix of the knee joint13.
These effects include, but are not restricted to, influencing
the synthesis of endogenous HA by synoviocytes14, pre-
venting the degradation of proteoglycan and collagen in
the extracellular matrix15, enhancing chondrocyte
metabolism16, inhibiting chondrodegradation17, preventing
apoptotic death of chondrocytes18 and inhibiting inflam-
matory responses that are associated with cartilage
degradation13,19.
A number of animal models have been developed to
evaluate the underlying pathologic progress of OA. These
models include meniscectomy and anterior cruciate
ligament transection (ACLT)16,20–26. Our laboratory has
previously shown that ACLT in rabbits initiates the
degenerative changes of OA26. Using gross morphologic
evaluation, the degenerative changes initiated by ACLT,
such as articular fibrillation and erosion, are progressive
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and easily observed. Histomorphometric analysis of the
joints subjected to ACLT allows for the changes
brought about by the breakdown of articular cartilage to be
quantified26.
In a previous study, we used the ACLT model to evaluate
the effects of one course of five weekly IA injections of HA
on the biochemical properties of the cartilage matrix during
the development of OA27. The results demonstrated a
positive effect of HA on the preservation of articular carti-
lage and synovial tissue. Because the structure-modifying
effects of treatment could be slow-acting, it is important to
evaluate these effects over the long term, and with more
than one course of treatment.
The objective of the present study was to examine the
long-term effect of two courses of IA injections of sodium
hyaluronate on the development of OA induced by transec-
tion of the anterior cruciate ligament in the rabbit knee joint.
Materials and methods
ANIMALS
Fifty New Zealand White (NZW) male and female rabbits
(weighing 3.7 kg±200 g, 1 year of age with closed epi-
physes) were used in this study. The female and male
rabbits were randomly divided into each group at a ratio of
50:50. The rabbits were divided into five groups of 10 each
after surgical ACLT and simple arthrotomy of their left
knees. All animals were sacrificed at week 26 of the study.
SURGICAL PROCEDURE
The surgical protocol was approved by the UCSD
Institutional Review Board. All rabbits were anesthetized
by an intra-muscular injection of ketamine (100 mg/kg)
and xylazine (8 mg/kg). The left knee was shaved and
disinfected with Betadine® solution. A medial parapatellar
incision was made through the skin and an arthrotomy
performed. The patella was dislocated laterally and the
knee placed in full flexion. The ACL was visualized and
transected with a no. 15 blade. The joint was then irrigated
with sterile saline and closed. The capsule and the syn-
ovium were closed together with a running suture of 4–0
prolene. The skin was closed with a running 3–0 nylon
mattress suture supplemented with interrupted sutures.
Postoperatively, the animals were permitted cage
activity (60 cm×60 cm×40 cm) without immobilization. The
animals were closely monitored for infections and other
complications.
EXPERIMENTAL DESIGN AND HYALURONAN INJECTIONS
Rabbits were divided into five treatment groups: Group 1
(ACLT only) underwent ACLT with no further treatment.
Group 2 (5HA+ACLT) underwent ACLT, followed by a
single course of five weekly sodium hyaluronate
(Hyalgan®) injections initiated 4 weeks after surgery.
Group 3 (5PBS+ACLT) underwent ACLT, followed by a
course of five weekly injections of phosphate-buffered
saline (PBS) vehicle. Group 4 (10HA+ACLT) was treated
as Group 2 but also received a second course of five
weekly sodium hyaluronate injections initiated at 13 weeks
postsurgery. Group 5 (10PBS+ACLT) was treated as Group
3 but also received a second course of five weekly PBS
injections initiated at 13 weeks postsurgery. All animals
were sacrificed at week 26 of the study, and both ACLT and
non-ACLT contralateral knees were harvested. The study
design is summarized in Fig. 1.
Rabbits receiving IA injections of sodium hyaluronate or
vehicle were anesthetized with ketamine (30 mg/kg) and
Fig. 1. Experimental design. ACLT=no injections following anterior cruciate ligament transection (ACLT); 5 HA=five weekly injections of
hyaluronan (HA) beginning on the 4th week after surgery; 5 PBS=five weekly PBS injections beginning on the 4th week after surgery;
10 HA=10 weekly HA injections, one course of five injections beginning on the 4th week after surgery and one course of five injections
beginning on the 13th week after surgery; 10 PBS=10 weekly PBS injections, one course of five injections beginning on the 4th week after
surgery and one course of five injections beginning on the 13th week after surgery.
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xylazine (2 mg/kg). The ACL transected knees were shaved
and disinfected with betadine solution. A 27-gauge needle
on a tuberculin syringe was inserted beneath the patella
in the region of the patellofemoral joint and 0.3 ml of
sodium hyaluronate (Hyalgan®, 10 mg/ml in PBS) or
vehicle (PBS) was injected in the intercondylar notch of the
femur between the medial and lateral femoral injections.
The injections were performed once weekly for 5 weeks, for
either one or two courses.
ASSESSMENTS
All gross morphological, histological, and histo-
morphometric analyses were performed by treatment-blind
personnel.
GROSS MORPHOLOGY
Gross morphological changes of the femoral condyles
were assessed as previously described26 according to the
following criteria after the application of India ink—grade 1
(intact surface): surface appears normal and does not
retain any ink; grade 2 (minimal fibrillation): site appears
normal before staining, but retains the India ink as
elongated specks or light gray patches; grade 3 (overt
fibrillation): the cartilage is velvety in appearance and
retains ink as intense black patches; grade 4 (erosion): loss
of cartilage exposing the underlying bone; grade 4a:
0 mm<erosion≤2 mm; grade 4b: 2 mm<erosion≤5 mm;
grade 4c: 5 mm<erosion. Gross morphological grade was
indicative of the entire joint. For comparison with histomor-
phometric analyses that assessed only the medial side,
both the medial and lateral grades were evaluated. The
overall joint grade was seen as the worse of the two
grades.
Joint effusion was graded on a scale of 0–3: 0=normal,
1=mild (fluid greater than normal, but does not fill the knee
joint), 2=moderate (fluid fills the knee joint, but does not
pour out of the capsule as it is opened), 3=severe (fluid
expands the knee joint and pours out as the capsule is
opened). The synovial fluid was aspirated from the lateral
suprapatellar area of the knee.
HISTOLOGICAL PREPARATION
The medial femoral condyles (ACLT and contralateral
controls) were divided sagitally into two equal parts. The
tissue blocks were fixed in 10% neutral-buffered formalin
with cetylpyridinium chloride (CPC) for 7 days and decalci-
fied with EDTA. After decalcification (confirmed by X-rays),
the two halves of the condyles were embedded in paraffin.
Five-micrometer sections, (three from each half) were cut
with a Reichert-Jung microtome and stained with Safranin
O/fast green. Synovia from each group were also pro-
cessed, embedded in paraffin, and stained with hematoxy-
lin and eosin (H&E) for cellular assessment by image
analysis.
HISTOMORPHOMETRY
Six Safranin O-stained sections from each medial con-
dyle were assessed and averaged using a color image
analysis system (Oncor Instrument Systems, USA). Histo-
logic sections were visualized with a microscope (Nikon
Microphot, Japan) and an attached high-resolution color
video camera (Hitachi HV-C10, Japan). Video images were
captured by high-definition video processing boards of the
image analysis system within the microcomputer (Everex
486/25, USA). Processed images were viewed on a high-
resolution color monitor (Sony Trinitron, Japan). Custom-
ized software was used to measure cartilage thickness and
area and surface roughness of cartilage, as well as thick-
ness of the synovial lining cell layer28. A 7-mm weight-
bearing section of the femoral condyle (taken from the
region of greatest cartilage damage) was defined and
analyzed. The thickness of cartilage from the surface to the
tide mark was calculated from the mean of five measure-
ments made perpendicularly to the surface of each section
at five equally spaced points. The area of the cartilage
present between the monitor screen edges was likewise
calculated. The thickness and area of cartilage were com-
puted using a mathematical algorithm with the coordinates
of articular cartilage and tide mark.
The surface profile of each specimen was assessed as
previously described26 by determining the surface rough-
ness. Calculation of cartilage roughness is based on the
deviations from an idealized smooth surface, which is
derived from shape parameters of normal cartilage outside
the region of degeneration. This parameter is expressed as
the root mean square (RMS) surface roughness calculated
from the following equation:
RMS surface roughnessS 1Ni1N (Yidealized iYreal i)2D
1/2
where N is the number of digitized points; Yidealized, i is the
theoretical coordinate of the idealized smooth surface of
articular cartilage determined from the coordinates of the
subchondral bone and mean thickness of the cartilage
region; and Yreal, i is the actual coordinate of the articular
cartilage surface.
Surface roughness is, in part, dependent on surface
thickness. Therefore, a meaningful calculation of surface
roughness normalized to cartilage thickness was made:
normalized cartilage roughness equals the RMS
roughness/cartilage thickness. All roughness data were
generated using this calculation26–28.
DNA CONCENTRATION (TISSUE CELLULARITY)
Relative cellularity in synovial tissue was assessed
by measuring the concentration of DNA as previously
described27,29. Water-washed and lyophilized synovial
tissue, 7–10 mg, were solubilized by incubation for 2 h in
3.0 ml of 1 N NaOH at 65°C. Duplicate 1.0-ml aliquots were
combined with 0.04% indole–HCl reagent and extracted
with chloroform to remove interfering substances. The
aqueous phase containing the DNA was removed, and the
absorbency was read at 490 nm. Standards of calf thymus
DNA were also determined for comparison. Results are
expressed as micrograms of DNA per milliliter of dry tissue.
STATISTICAL ANALYSIS
To establish differences between ACLT and contralateral
control joints for all parameters, a two-tailed t-test using
paired sets of data was employed. To evaluate differences
in ACLT data between treatment groups, analyses of vari-
ance using unpaired data sets were employed. The level of
significance for each type of analysis was set at 0.05.
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Results
Four rabbits were eliminated from the study and were
replaced to maintain 10 animals per study group. One
rabbit died suddenly from an unknown reason, one was
sacrificed because it had a toe infection, another because it
had a swollen foot resulting from an injury in the cage, and
one rabbit had a broken back in the postoperative course.
No adverse reactions to sodium hyaluronate or vehicle
injections were noted in any of the treated animals.
GROSS MORPHOLOGICAL ASSESSMENT
All specimens exhibited changes consistent with the
development of chronic OA and showed severe degrada-
tion of the femoral condyle cartilage and tibial plateau.
Despite the finding that the general appearance of the
harvested knees was poor for all groups, the groups that
received either one or two courses of HA injections follow-
ing ACLT exhibited slightly greater resistance to the
changes of OA than did the groups that received two
courses of vehicle or no treatment alone: 2 of 10 rabbits
that received 10 HA injections (Group 4) exhibited only
grade 3 morphology in the femoral condyle (Table I).
However, the group that received one course of vehicle
injections also exhibited good morphological scoring in the
femoral condyle. Three of 10 rabbits in Group 2 and Group
3 (5HA+ACLT and 5PBS+ACLT, respectively) exhibited
only grades 2 or 3 morphology. All of the joints from the
group that received two courses of vehicle injections after
ACLT were grade 4b or worse, which indicates lesions of at
least 2 mm in the cartilage exposing the bone. This finding
was consistent for both the femoral condyles and tibial
plateaus.
All rabbits exhibited some degree of mild to moderate
joint effusion, i.e. 200 µl of fluid compared with 100 µl of
normal synovial fluid in the rabbit knee. This amount was
not significant, however, for any group: 44 rabbits exhibited
grade 1, and 6 rabbits exhibited grade 2.
In almost all of the animals at 26 weeks after ACLT,
the medial menisci were completely torn and the lateral
menisci were either reversed or shifted medially because of
the weight-bearing shift toward the posterior. All of the
medial menisci in Group 1 (ACLT only), Group 2 (5HA+
ACLT), Group 3 (5PBA+ACLT), and Group 5 (10PBS+
ACLT) were torn. In contrast, 2 of 10 medial menisci in
Group 4 (10HA+ACLT) were not torn. Therefore, only the
group that received two courses of sodium hyaluronate
injections demonstrated any menisci that were not torn
(Fig. 2).
DNA CONTENT IN SYNOVIAL TISSUE
The measurement of DNA content in the synovial
tissue is an index of inflammation and cellular proliferation.
Results from this study showed that the specimens
from Group 2 (5HA+ACLT), Group 3 (5PBS+ACLT), and
Group 4 (10HA+ACLT) had significantly lower DNA concen-
trations (P<0.05) in the tissues when compared with that in
Group 1 (ACLT only) and Group 5 (10PBS+ACLT) (Fig. 3).
There were no significant differences between Group 2,
Group 3, and Group 4 with regard to this parameter, nor
was there any difference between the joints that underwent
ACLT and non-ACLT contralateral control joints within each
of these three groups.
HISTOMORPHOMETRY
Based on visual assessment of histologic staining, the
general condition of the femoral condyles was poor in all of
the groups (data not shown). Histomorphometrically, there
was a significant decrease in both measured height and
measured area of cartilage in ACLT joints compared with
contralateral control joints in all of the groups [Fig. 4(a and
b)]. No difference was detected between the cartilage
heights and areas of any of the experimental groups, which
exhibited mostly grade 4 cartilage as indicated by gross
morphological assessment (Table I).
In contrast to the findings regarding cartilage height and
area, significant differences were identified between treat-
ment groups in the surface roughness characteristics. All of
the femoral condyles demonstrated a significant increase
in RMS roughness over the contralateral control joints
(P<0.05) (Fig. 4c). However, Group 4 (10HA+ACLT) exhib-
ited significantly less RMS roughness than Group 1 (ACLT)
and Group 5 (10PBS+ACLT) for both the tibia and femur
(P<0.05). Roughness was also significantly lower in Group
Table I
Distribution of OA grades by gross morphological assessment of the articular cartilage from the femoral condyle and tibial plateau
Grade Group 1
ACLT only
(N=10)
Group 2
5 HA injections+ACLT
(N=10)
Group 3
5 PBS injections+ACLT
(N=10)
Group 4
10 HA injections+ACLT
(N=10)
Group 5
10 PBS injections+ACLT
(N=10)
Femoral condyle
1 0 0 0 0 0
2 0 1 1 0 0
3 1 2 2 2 0
4a 1 0 1 0 0
4b 2 3 1 2 5
4c 6 4 5 6 5
Tibial plateau
1 0 3 0 3 0
2 2 0 3 2 0
3 0 0 0 0 0
4a 0 1 0 0 0
4b 6 4 4 4 8
4c 2 2 3 1 2
Grade 1=intact surface; grade 2=minimal fibrillation; grade 3=overt fibrillation; grade 4a=0 mm<erosion≤2 mm; grade 4b=
2 mm<erosion≤5 mm; grade 4c=5 mm<erosion.
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Fig. 2. Gross morphology of the meniscus in representative samples taken at 26 weeks after surgery from (a) Group 4 (10 HA+ACLT) and
(b) Group 1 (ACLT only).
Fig. 3. DNA concentration in synovium from medial femoral condyles (mean±SD). Results are shown for ACLT and non-ACLT (untreated)
control knees for each study group. N10 for each group.
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4 (10HA+ACLT) than that seen in the tibia for Group 3
(5PBS+ACLT) and than that seen in the femur for Group 2
(5HA+ACLT) (P<0.05 for both comparisons). Group 3
(5PBS+ACLT) exhibited significantly lower femoral rough-
ness than Group 1 (ACLT only), Group 2 (5HA+ACLT), and
Group 5 (10PBS+ACLT) (P<0.05 for all comparisons). Only
Group 4 (10HA+ACLT) had significantly less tibial rough-
ness than Group 2 (5PBS+ACLT) (P<0.05). These results
indicate a significant benefit of two courses of HA injections
with regard to surface roughness following ACLT as com-
pared with no HA treatment, or treatment with only one
course of HA injections.
Discussion
The results of the present study indicate that repeat
courses of HA injections reduced the degree of articular
degradation in an animal model of OA. Administration
of two courses of HA, totaling 10 injections, resulted in
significantly less OA progression at 26 weeks after surgery
than did no treatment, one or two treatment courses of
vehicle, or only one course of five weekly HA injections.
This beneficial effect was especially apparent with regard to
prevention of degradation of cartilage of the tibial plateau.
Gross morphological assessment of the menisci also indi-
cated that repeat courses of HA injections may help to
prevent changes associated with the progression of OA:
only the group that had two courses of HA injections (10
injections total) produced any samples in which the medial
menisci were not torn.
Open-label and steroid-controlled studies used
arthroscopy and electron microscopic assessment of
paired biopsy samples to demonstrate that one course of
five weekly Hyalgan® injections produced significant recon-
stitution of the cartilage, improvement in chondrocyte
metabolism, and reduction in inflammation of the synovial
membrane30–32. Another recent study demonstrated that
three courses of three weekly injections of Hyalgan® sig-
nificantly reduced progression of joint space-narrowing in
the subset of patients with the most severe narrowing at
study entry33.
It is likely that pharmacotherapeutic modification of OA
disease progression will be a slower process than that of
providing symptom relief. Therefore, meaningful clinical
effects may require longer-term exposure to the therapeutic
modality. Because of this likelihood, the OARS recom-
mends that clinical studies designed to evaluate the
structure-modifying effects of drugs for OA treatment
should be performed over at least a 1-year period. The
present study in an animal model of OA evaluated the
effects of HA after a 26-week follow-up period, and
revealed that two courses of HA injections provided a
benefit compared with one course of injections for slowing
OA progression. These results indicate that the long-term
structure-modifying effects of repeat treatment courses of
HA should be further evaluated in patients with OA of the
knee.
In conclusion, the results of this study indicate that repeat
courses of HA injections in an ACLT rabbit model of OA can
reduce the degree of articular degeneration observed over
a 26-week follow-up period compared with no treatment,
one course of HA injections, or one or two courses of
injections of vehicle only. Consistent with recent clinical
findings of structure modification by HA, these results
suggest the possibility that HA treatment may be able to
modify the progression of OA of the knee, and it may have
advantages in the long-term management of this disease.
Hyalgan® is a sodium hyaluronate product that has been
found to be safe and effective in the ACLT rabbit model
when given in repeat treatment courses, and this may
provide the benefit of mediating symptom relief and exert-
ing a structure-modifying effect when used in repeat
courses over the long term.
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